Comprehensive preclinical assessment of stem cell therapies is critical for regulatory approval and to ensure safety in first-in-human clinical trials. Here are some tips to consider for a successful translational cell therapy program.
Bridge the gap from in vitro to in vivo models with our new European microinjection platform.
Discovery from Charles River has licensed a new model for Alzheimer’s disease in vivo studies.
Learn about ion channel trafficking effects and CiPA in our latest publication, featured in Scientific Reports.
Anterior segment optical coherence tomography (OCT) rounds out our ability to image the eye via a noninvasive method.
MEA technology facilitates stimulation and monitoring of neural circuits with a single chip.
The assessment of electrical signals from stem-cell-derived human cardiomyocytes is a valuable component in the developing comprehensive in vitro proarrhythmia assay (CiPA).
As another year comes to a close, we celebrate the successes we’ve shared with you, and look forward to all that we can accomplish together in 2016.
Charles River is pleased to announce that our 2016 Research Models and Services catalogs are now available electronically.
Over 150 attendees had the opportunity to hear 19 leading experts from academia and industry present their work. The scientific-focused events facilitated a lively and interactive networking opportunity, with several of the attendees presenting their findings through posters.